Gliclazide mV Table with modif.vysv. 60 mg 30 pcs ozone

Description

Composition
Active substance:
1 tablet contains: gliclazide – 30.0 mg or 60.0 mg.
Product form:
The modified-release tablets of 30 mg or 60 mg. At 10, 14, 25, 30 tablets in blisters of PVC film and aluminum foil printed patent. 10, 20, 30, 40, 50, 60 or 100 tablets in banks of polyethylene terephthalate or polypropylene jars for medicaments. One jar or 1, 2, 3, 4, 5, 6 or 10, the contour of cellular upakovokvmeste with instructions for use placed in a cardboard box (pack).
Contraindications
Hypersensitivity to gliclazide or any of the excipients of the drug, other derivatives of sulfonylureas, sulfonamides; type 1 diabetes; diabetic ketoacidosis, diabetic precoma, diabetic coma; severe renal or hepatic impairment; receiving miconazole; pregnancy and lactation; age 18 years. It is not recommended to use simultaneously a drug in combination with phenylbutazone or danazol.
Dosage
60 ur
Indications
Type 2 diabetes is the lack of effectiveness of diet therapy, exercise and weight loss. Prevention of complications of diabetes: reduced risk of microvascular (nephropathy, retinopathy) and macrovascular disease (myocardial infarction, stroke) in patients with type 2 diabetes by intensive glycemic control.
pharmachologic effect
Pharmacological group:
Hypoglycemic agent for oral administration group II generation sulfonylureas
ATC code A10VV09.
Pharmacological properties:
Gliclazide is a derivative of sulfonylurea hypoglycemic drug for oral administration which is characterized by the presence of similar medications containing N-heterocyclic rings endocyclic bond. Gliclazide reduces the concentration of blood glucose by stimulating insulin secretion by beta cells of the islets of Langerhans. Increasing concentrations of postprandial insulin and C-peptide is retained after 2 years of therapy. Besides effects on carbohydrate metabolism has gliclazide hemovascular effects. In type 2 diabetes gliclazide restores early peak of insulin secretion in response to glucose intake and increases the second phase insulin secretion. A significant increase is observed in insulin secretion in response to stimulation due to ingestion or administration of glucose. Gliclazide reduces the risk of thrombosis small vessels, affecting the mechanisms that may cause complications in diabetes: partial inhibition of platelet aggregation and adhesion and a decrease in the concentration of platelet activating factors (beta thromboglobulin, thromboxane B2) and for the restoration of the fibrinolytic activity of vascular endothelial and increase activity of tissue plasminogen activator. Intensive glycemic control is based on the use of gliclazide modified release (target glycated hemoglobin (HbA1c)
Conditions of supply of pharmacies
Prescription.
Dosing and Administration
The drug is intended for adults only. The recommended dose of the drug should be taken orally, 1 time / day, preferably at breakfast time. The daily dose is 30-120 mg (1-4 tablets) 1 reception. It is recommended to swallow the tablet whole without chewing or crushing. When you pass one or more administrations of the drug should not take a higher dose to the next appointment, the missed dose should be taken the next day. As with other hypoglycemic drugs, the drug dose in each case should be selected individually depending on the concentration of blood glucose and glycosylated hemoglobin (HbA1c). Starting recommended dosage in adults previously treated with the treatment (including elderly persons older than 65 years) – 30 mg / day (one tablet), then the dose is adjusted individually to achieve the desired result. When the drug Gliclazide MB replace other hypoglycemic agents do not need any transitional period. You first need to stop taking this drug and only then take the drug Gliclazide MB. Dose selection must be performed in accordance with the indicator concentration in the blood glucose after treatment. Each successive change in dose can be taken after a minimum period of two weeks. Supportive daily dose is from 1 to 3-4 tablets, and should not exceed 120 mg. Gliclazide CF can be combined with biguanides, alpha-glucosidase inhibitor or insulin. Recommended for the elderly doses are identical to those for adults up to 65 years. The recommended dose in renal failure mild to moderate severity identical to those persons with normal renal function. In patients at risk of hypoglycaemia (poor diet, severe or poorly compensated endocrine disorders – pituitary and adrenal insufficiency, hypothyroidism; abolition of corticosteroids after long-term use and / or receiving high doses, severe diseases of the cardiovascular system ( severe coronary heart disease, severe carotid atherosclerosis, arteriosclerosis common) it is recommended to use the lowest dose (30 mg) Gliclazide MV preparation. For achievements Ia intensive glycemic control can gradually increase the dose of the drug Gliclazide MW to 120 mg / day, in addition to diet and exercise to achieve a HbA1c target level. It should be aware of the risk of hypoglycemia. In addition, treatment can add other hypoglycemic drugs, e.g., metformin, alpha-glucosidase inhibitor, a thiazolidinedione derivative or insulin.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist